-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Recently, new pharmaceutical and biological stocks in the A-share market have frequently broken.
Among them, Haichuang Pharmaceutical and Maiwei Bio have fallen by more than 30% on the first day of listing
.
In fact, since July 2021, the pharmaceutical and biological sector has begun to pull back.
Wind information shows that from July 1, 2021 to April 22, 2022, the CSI Shenwan Pharmaceutical Biological Index has pulled back 39.
69%
.
More than 90% of the stocks in the sector fell
.
Even innovative drug companies have seen a correction of more than 50% in their stock prices since 2022, including A-share Changchun Hi-Tech, WuXi AppTec, etc.
, as well as some companies in Hong Kong stocks
.
From the perspective of adjustment reasons, the main reason is that the "bubble" of innovative drugs will burst
.
Some in the industry even predict that more than 1,000 biopharmaceutical companies will disappear in 2022
.
What is the reason behind this? In July 2021, the Center for Drug Evaluation (CDE) of the State Food and Drug Administration issued a notice on the public solicitation of opinions on the "Guiding Principles for Clinical Research and Development of Antitumor Drugs Oriented to Clinical Value", requiring that new drug research and development "focus on patient needs, Guided by clinical value”, referring to the current domestic innovative drug targets, the proliferation of “Me-too” (similar to innovative drugs), low-level repetition, and lack of real innovation
.
This
new policy is also regarded by the industry as innovation .
A new round of supply-side reform of medicine
.
The
so-called Me-too medicine refers to the research and development (modification) of a similar medicine on the basis of the original research medicine
.
In China, the research and development of Me-too medicine is hot, PD-1 (L1) and other competitions The road is becoming more and more crowded, and the industry believes that the State Food and Drug Administration's "shot" will help combat "pseudo-innovation", thereby preventing the overheating of certain drug R&D directions and R&D product categories, avoiding vicious competition among industry enterprises, and forcing the industry to develop.
will tend to be benign
.
For innovative drug companies, the release of the above-mentioned new policy clearly puts forward higher research and development requirements, that is, the development of new drugs in the future must prove to be better than existing treatments, which also means that the difficulty of developing new drugs for pharmaceutical companies is greatly increased
.
So, as the "bubble" of innovative drugs will burst, what is the way out for local companies to break through in the future? Some industry analysts believe that the way out may be based on the premise of "researching and developing real new drugs that meet market demand", and making new innovative drugs with high competition barriers and market windows
.
However, pharmaceutical R&D has the characteristics of high investment and high risk, and its difficulty is self-evident.
In this regard, listed people suggest that pharmaceutical companies can also seek some breakthroughs
.
For example, using "new China" targets combined with policies and enterprises (R&D technology, R&D direction, etc.
) to make differentiated innovative drugs; according to policies to protect people's livelihood and increase the availability of drugs for patients; to meet unmet clinical needs of tumors, Innovative drugs
in the neurological field, etc.
Many pharmaceutical companies have their own thoughts after the release of the draft of the new policy
.
For example, Pharmaron said that its current business is still dominated by overseas customers, and the goal of most customer projects is to develop new drugs with clinical value on a global scale
.
The above-mentioned guiding principles newly released by the state are in line with the company's judgment on the overall trend of the industry in the future.
Tigermed believes that in recent years, national policies have always emphasized the clinical value of new drugs and encouraged innovative drug companies to improve the quality of innovation
.
As a CRO company, Tigermed has always carefully selected customers and projects, hoping to help more clinically valuable drug research
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
Among them, Haichuang Pharmaceutical and Maiwei Bio have fallen by more than 30% on the first day of listing
.
In fact, since July 2021, the pharmaceutical and biological sector has begun to pull back.
Wind information shows that from July 1, 2021 to April 22, 2022, the CSI Shenwan Pharmaceutical Biological Index has pulled back 39.
69%
.
More than 90% of the stocks in the sector fell
.
Even innovative drug companies have seen a correction of more than 50% in their stock prices since 2022, including A-share Changchun Hi-Tech, WuXi AppTec, etc.
, as well as some companies in Hong Kong stocks
.
From the perspective of adjustment reasons, the main reason is that the "bubble" of innovative drugs will burst
.
Some in the industry even predict that more than 1,000 biopharmaceutical companies will disappear in 2022
.
What is the reason behind this? In July 2021, the Center for Drug Evaluation (CDE) of the State Food and Drug Administration issued a notice on the public solicitation of opinions on the "Guiding Principles for Clinical Research and Development of Antitumor Drugs Oriented to Clinical Value", requiring that new drug research and development "focus on patient needs, Guided by clinical value”, referring to the current domestic innovative drug targets, the proliferation of “Me-too” (similar to innovative drugs), low-level repetition, and lack of real innovation
.
This
new policy is also regarded by the industry as innovation .
A new round of supply-side reform of medicine
.
The
so-called Me-too medicine refers to the research and development (modification) of a similar medicine on the basis of the original research medicine
.
In China, the research and development of Me-too medicine is hot, PD-1 (L1) and other competitions The road is becoming more and more crowded, and the industry believes that the State Food and Drug Administration's "shot" will help combat "pseudo-innovation", thereby preventing the overheating of certain drug R&D directions and R&D product categories, avoiding vicious competition among industry enterprises, and forcing the industry to develop.
will tend to be benign
.
For innovative drug companies, the release of the above-mentioned new policy clearly puts forward higher research and development requirements, that is, the development of new drugs in the future must prove to be better than existing treatments, which also means that the difficulty of developing new drugs for pharmaceutical companies is greatly increased
.
So, as the "bubble" of innovative drugs will burst, what is the way out for local companies to break through in the future? Some industry analysts believe that the way out may be based on the premise of "researching and developing real new drugs that meet market demand", and making new innovative drugs with high competition barriers and market windows
.
However, pharmaceutical R&D has the characteristics of high investment and high risk, and its difficulty is self-evident.
In this regard, listed people suggest that pharmaceutical companies can also seek some breakthroughs
.
For example, using "new China" targets combined with policies and enterprises (R&D technology, R&D direction, etc.
) to make differentiated innovative drugs; according to policies to protect people's livelihood and increase the availability of drugs for patients; to meet unmet clinical needs of tumors, Innovative drugs
in the neurological field, etc.
Many pharmaceutical companies have their own thoughts after the release of the draft of the new policy
.
For example, Pharmaron said that its current business is still dominated by overseas customers, and the goal of most customer projects is to develop new drugs with clinical value on a global scale
.
The above-mentioned guiding principles newly released by the state are in line with the company's judgment on the overall trend of the industry in the future.
Tigermed believes that in recent years, national policies have always emphasized the clinical value of new drugs and encouraged innovative drug companies to improve the quality of innovation
.
As a CRO company, Tigermed has always carefully selected customers and projects, hoping to help more clinically valuable drug research
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
